Glenmark is a USD 1.48 bn global pharmaceutical organisation with over 14,000 employees in 50 countries, deriving more than 70% of our revenues from international markets. Our 14 manufacturing facilities across four countries, support our commercial presence across 80 countries. Glenmark has a significant presence in the branded generics markets across emerging economies including India. The Generics business of Glenmark services the requirements of the US and Western European markets. Glenmark’s API business works with 16 of the 20 largest generic companies globally (source: A Year of Surprises Shakes Up Off-Patent Industry” | Informa, 2020) and serves customers in multiple regions, including North America, Europe, Japan, Latin America, India and ROW.

Key highlights:

• Ranks among the world’s top 50 Generics and Biosimilars companies (As per the Top 50 Company Rankings, 2020, from Informa’s Generics Bulletin).
• As per IQVIA MAT March 2021, Glenmark was the fastest growing company in the industry among the Top 20 players in India.
• As per IQVIA MAT March 2021, Glenmark is ranked 2nd in the overall Dermatology and anti-viral markets, and 6th in the cardiology market in India.
• Glenmark’s marketing portfolio through March 31, 2021 consists of 171 generic products authorized for distribution in the U.S. market.
• As per IQVIA MAT March 2021, ranks 11th in the dermatology segment and 3rd in the expectorants segment in Russia.

Partnership is an integral part of our business strategy and we are keen to collaborate with partners who support us in our mission of enriching lives of patients by offering them high-quality and affordable medication.